PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Schmidt, Amand F ^a   Pearce, Lucy S ^b   Wilkins, John T ^c   Overington, John P ^d   Hingorani, Aroon ^a   Casas, Juan Pablo ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

^d EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PCSK9; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITION; DRUG SAFETY; HUMAN; INCIDENCE; MALIGNANT NEOPLASM; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SYSTEMATIC REVIEW;

EID: 85009876004     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011748     Document Type: Article

References (38)

1. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
2. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. Journal of the American College of Cardiology 2010;55(22):2833-42.
3. Breitling LP, Brenner H. Odd odds interactions introduced through dichotomisation of continuous outcomes. Journal of Epidemiology and Community Health 2010;64(4):300-3.
4. Capewell S, Allender S, Critchley J, Lloyd-Williams F, O'Flaherty M, Rayner M, et al. Modelling the UK Burden of Cardiovascular Disease to 2020: A Research Report for the Cardio & Vascular Coalition and the British Heart Foundation. British Heart Foundation, 2008. http://www.healthimpact.org.uk/Home/Links (accessed 01 February 2015).
5. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228(1):18-28.
6. Chasman DI,Giulianini F,MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced lowdensity lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circulation. Cardiovascular Genetics. 2012;5(2):257-64.
7. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics 2005;37(2):161-5.
8. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine 2006;354(12):1264-72.
9. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493): 1267-78.
10. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2005;385(9976):1397-405.
11. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet 2012;380(9841):581-90.
12. D'Agostino RB Sr, Vasan RS, Pencina MJ,Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in Primary Care: the Framingham heart study. Circulation 2008;117(6):743-53.
13. Farnier M. PCSK9: From discovery to therapeutic applications. Archives of Cardiovascular Disease 2014;107 (1):58-66.
14. Ganna A, Magnusson PK, Pedersen NL, de Faire U, Reilly M, Arnlöv J, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arteriosclerosis, Thrombosis, and Vascular Biology 2013;33(9):2267-72.
15. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-1494.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 2004;44(3):720-32.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
18. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Greene S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
20. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. European Heart Journal 2014;36(9):539-50.
21. Kreatsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. Canadian Journal of Cardiology 2010;26(Suppl C):8C-13C.
22. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Global Health 2013;1(5): e259-81.
23. Lunven C, Paehler T, Poitiers F, Brunet A, Rey J,Hanotin C, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovascascular Therapy 2014;32(6):297-301.
24. Moran AE, Forouzanfar MH, Roth GA,Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014;129(14):1493-501.
25. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197-223.
26. Navarese EP, Ko odziejczak M, Schulze V, Gurbel PA, Tantry U, et al. Effects of proprotein convertase subtilisin/ kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Annals of Internal Medicine 2015 April 28 [Epub ahead of print]. [DOI: 10.7326/M14-2957]
27. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in Medicine 1998;17(8):873-90.
28. R Development Core Team 2014 [Computer program] R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
29. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18-209.
30. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New England Journal of Medicine 2015;372(16):1500-9.
31. Schmidt AF, Groenwold RH, Knol MJ, Hoes AW, Nielen M, Roes KC, et al. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. Journal of Clinical Epidemiology 2014;67(7):821-9.
32. Schmidt AF, Hoes AW, Groenwold RH. Comments on 'the use of propensity scores and observational data to estimate randomized controlled trial generalizability bias' by Taylor R. Pressler and Eloise E. Kaizar, Statistics in Medicine 2013. Statistics in Medicine 2014;33(3):536-7.
33. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences of the United States of America 2003;100(3):928-33.
34. Shah S, Casas JP, Drenos F, Whittaker J, Deanfield J, Swerdlow DI, et al. Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. Circulation. Cardiovascular Genetics 2013;6(1):63-72.
35. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2014;385 (9965):351-61.
36. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Statistics in Medicine 2002;21(11):1559-73.
37. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323(7321):1123-4.
38. WHO 2008 World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_ burden_disease/2004_report_update/en/ (accessed 01 February 2015).